AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Episurf Regulatory Filings 2019

Jun 11, 2019

3157_iss_2019-06-11_d3d3f3f7-23f2-4f9b-bc1f-d97d474ed9a3.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

New Japanese patent approval for Episurf Medical

The Japanese patent office JPOhas announced its intention to grant another Japanese patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled "Surgical kit for cartilage repair comprising implant and a set of tools", has a focus on the company's individualised Episealer® Femoral Twin joint implant and its design.

"The Episealer® twin technology is an appreciated solution for the commonly occurring elongated cartilage lesions, and we hereby strengthen the IP portfolio globally for that part of our technology platform", comments Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: [email protected]

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.30 CEST on 11 June 2019.